1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Harbin Medisan Pharmaceutical Co., Ltd.

Harbin Medisan Pharmaceutical Co., Ltd.

002900.SZ
Harbin Medisan Pharmaceutical Co., Ltd.CN flagShenzhen Stock Exchange
9.57
CNY
-0.05
- -
3.03BMarket Cap
Harbin Medisan Pharmaceutical Co., Ltd.
002900.SZ
(Shenzhen Stock Exchange)

Recent

price

9.57

P/E

ratio

- -

div

yld

- -

ROIC.AI

2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
31.47
2.69
2.94
3.04
3.21
4.5
6.86
6.76
4.11
3.05
3.4
3.87
3.67
2.49
3.19
Revenue per Share
5.3
0.47
0.63
0.7
0.74
0.71
0.65
0.57
0.09
1.13
0.1
0.24
0.19
-1.07
-0.19
Basic EPS, GAAP
-5.83
-0.69
-0.13
0.25
0.58
0.46
0.68
0.39
-0.46
-0.28
0.18
-0.86
-1.02
-0.89
-0.88
Free Cash Flow per Basic Share
0.3
0.19
0.23
0.23
0.39
0.36
0.34
0.67
0.29
0.11
0.36
0.13
0.34
0.35
0.34
Dividend per Share
20.55
0.72
1.3
1.69
1.96
2.36
2.45
2.34
2.02
3.08
2.94
3.03
2.99
1.64
2.4
Book Value per Share
17.29
1.34
2.35
2.8
3.16
6.96
5.95
5.7
5.27
6.58
6.55
6.53
6.51
5.01
5.73
Tangible Book Value per Share
16
224
232
238
237
255
317
311
326
311
302
307
309
317
321
Basic Weighted Avg Shares
491
601
682
722
761
1,149
2,173
2,102
1,339
946
1,028
1,187
1,132
789
1,022
Sales/Revenue/Turnover
23.24
24.35
24.61
25.31
27.12
20.25
9.92
9.9
4.56
-13.62
-1.62
1.44
4.45
-34.87
-4.41
Operating Margin (%)
- -
- -
36
47
58
69
74
79
80
99
107
109
111
143
- -
Depreciation Expense
83
104
147
166
175
181
206
177
29
351
30
74
59
-340
-60
Net Income, GAAP
15.09
14.63
15.77
16
16.23
28.44
17.95
23.82
19.68
22.78
33.87
13.88
8.38
- -
39.72
Effective Tax Rate (%)
16.84
17.36
21.57
23.03
23.02
15.76
9.47
8.43
2.19
37.11
2.94
6.21
5.18
-43.02
-5.87
Profit Margin (%)
-25
-116
33
57
68
1,092
1,194
962
844
891
1,026
591
214
-149
19
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
11
213
423
238
139
277
157
LT Debt
343
365
609
728
808
1,835
1,966
1,852
1,792
2,116
2,052
2,148
2,164
1,775
2,008
Total Equity
- -
25.44
22.55
19.83
19.59
11.85
9.05
7.77
2.38
-4.26
-0.42
0.53
1.55
- -
- -
Return on Invested Capital (%)
- -
31.9
44.14
38.14
33.67
31.46
28.62
20.8
4.18
29.94
3.24
6.04
5.16
- -
8.4
Return on Capital (%)
- -
43.32
63.57
47.26
40.38
33.91
29.85
23.56
4.23
43.49
3.28
8.11
6.33
-46.96
-7.22
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
797
664
681
LT Borrowings
134
160
153
LT Finance Leases
5
4
4
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
316
316
316
Market Capitalization
3,085
3,221
4,567

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
1,472
1,352
1,162
Cash, Cash Equivalents & STI
842
724
587
Accounts Receivable, Net
209
170
137
Inventories
308
321
314
Total Current Liabilities
1,258
1,165
1,143
Payables & Accruals
- -
- -
- -
ST Debt
797
664
681
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
13.87%
0.5%
-17.99%
Free Cash Flow
-84.1%
-154.63%
-10%
Net Income, GAAP
37.51%
90.01%
-678.82%
Sales/Revenue/Turnover
6.58%
-8.02%
-30.29%
Total Cash Common Dividend
37.92%
50.45%
5.47%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
247
277
315
294
1,132
2025
205
208
209
- -
789
2026
229
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.06
- -
- -
- -
0.19
2025
-0.09
- -
- -
- -
-1.07
2026
-0.02
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
- -
- -
- -
0.34
2025
0.07
- -
- -
- -
0.35
2026
0.02
- -
- -
- -
- -
Similar Companies
Windlas Biotech Limited (WINDLAS.BO)
RCMW Group, Inc. (RCMW)
Octavia Wellness Inc. (OCTVV)
Prince Pharmaceutical Co., Ltd. (6935.TWO)
ShanXi C&Y Pharmaceutical Group Co., Ltd. (300254.SZ)
PolyPeptide Group AG (0AAJ.L)
Business
Harbin Medisan Pharmaceutical Co., Ltd. (002900.SZ) engages in the research, development, production, and sale of chemical pharmaceutical preparations, specialty active pharmaceutical ingredients (APIs), and medical devices primarily in China. Founded in 1996 and headquartered in Harbin, China, the company operates as a national high-tech enterprise with a focus on multiple dosage forms including tablets, injections, and infusions for domestic and foreign markets; its core products encompass nervous system drugs such as mirtazapine tablets, olacetam injections, piracetam injections, and injectable brain protein hydrolysate (III); cardiovascular treatments including edaravone injections, ligustrazine hydrochloride for injection, esprolol hydrochloride for injection, pentoxifylline injections, and sodium ferulate; musculoskeletal therapies like injectable bone peptides, loxicam for injection, and sodium osteopeptide chloride injections; anti-infectives such as rifamycin sodium for injection and clindamycin phosphate injection; basic and nutritional infusions including sodium chloride injection, glucose injection, alanyl glutamine injection, hydroxyethyl starch 130/0.4 sodium chloride injection, and compound amino acid injection (18AA-III); as well as metabolism drugs like methylcobalamin injection and others including valsartan dispersible tablets and sarcosinopeptide for injections. The company targets healthcare providers and patients across various therapeutic segments with approximately 2,522 employees and maintains GMP-certified facilities for lyophilized powders, small-volume injections, and large-volume infusions. In recent developments, Harbin Medisan Pharmaceutical's diltiazem hydrochloride injection and potassium chloride and sodium chloride injection pass consistency evaluations for generic drug quality and efficacy; it secures approvals for new products including triptorelin acetate injection in September 2024 and potassium chloride injection in May 2024; and reports operating revenue growth in its 2025 semi-annual results amid a focus on innovative pharmaceuticals and commercial insurance pathways.